Enzo Biochem's Clinical Labs Unit Named a Participant in Empire BlueCross BlueShield Provider Network

NEW YORK--(BUSINESS WIRE)-- Enzo Biochem Inc.'s (NYSE: ENZ) wholly-owned subsidiary, Enzo Clinical Labs, Inc., and Empire BlueCross BlueShield, the largest health insurer in New York State, today jointly announced that effective August 1, 2010 Enzo Clinical Labs will be a participating laboratory in the Empire provider network for the metropolitan New York area.

The Empire provider network to be covered includes Empire PPO Plans, Empire EPO Plans and Empire Indemnity Plans. Enzo Clinical Labs provides clinical, cytology and anatomic pathology services, in addition to a comprehensive menu of genetic and ancillary testing, and customized test panels and profiles.

"We are very appreciative of being appointed a participating laboratory in the Empire provider network," said Kevin Krenitsky, M.D., President of Enzo Clinical Labs. "Empire BlueCross BlueShield is a major standard setter for quality patient healthcare, and similarly we at Enzo Labs' share a commitment to excellence and the use of advanced testing and technology to benefit patient care. We are thus proud of this new association, and look forward to contributing meaningfully to the services Empire provides."

"Enzo Clinical Labs has demonstrated capabilities that will benefit the high level of healthcare which is our hallmark, and we are pleased to welcome them as a participating laboratory to our network," said Jill R Hummel, Vice President, Health Services of Empire BlueCross BlueShield.

About Enzo Biochem

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Clinical Labs provides laboratory services for a growing roster of physicians in the New York Metropolitan area. Its tests include, in addition to routine tests, capabilities for detecting molecular infection disease, molecular oncology, autoimmune disorders and genetics. Enzo Clinical Labs also provides clinical diagnostic services that allow Enzo to capitalize on its extensive advanced molecular and cytogenetic capabilities and the broader trends in predictive and personalized diagnostics.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

    Source: Enzo Biochem Inc.

Released August 2, 2010